发明名称 |
Method for treating psoriasis |
摘要 |
The present invention provides a pharmaceutical composition for treating an autoimmune disease comprising a pharmaceutically acceptable carrier and an agent capable of activating CD4+CD25+ regulatory T cells, wherein the composition is to be administered to a subject in a dose of the agent from 0.2 mg to 30 mg. |
申请公布号 |
US9334325(B2) |
申请公布日期 |
2016.05.10 |
申请号 |
US201012880837 |
申请日期 |
2010.09.13 |
申请人 |
BIOTEST AG |
发明人 |
Osterroth Frank;Aigner Silke;Germer Matthias;Uherek Christoph;Kraus Elmar;Wartenberg-Demand Andrea;Wolf Daniele;Kaiser Sibylle;Lindner Juergen;Bruecher Christoph;Daelken Benjamin |
分类号 |
A61K39/395;C07K16/28;A61K39/00 |
主分类号 |
A61K39/395 |
代理机构 |
Cermak Nakajima & McGowan LLP |
代理人 |
Cermak Shelly Guest;Cermak Nakajima & McGowan LLP |
主权项 |
1. A method for treating an autoimmune disease comprising administering to a subject a pharmaceutical composition comprising a pharmaceutically acceptable carrier and an agent capable of activating CD4+CD25+ regulatory T cells, wherein said administering comprises administering said composition to the subject intravenously in a dose of the agent of from 0.3 mg to 5 mg, weekly, every two weeks, every four weeks, or every calendar month, wherein the agent is a humanized anti-CD4 antibody comprising an IgG1 constant domain, an H chain V domain comprising SEQ ID NO: 1 and an L chain V domain comprising SEQ ID NO: 2, and wherein the autoimmune disease is psoriasis. |
地址 |
Dreieich DE |